SCHEMBL10273787

SCHEMBL10273787

CCCc1cccc(C(=O)NCc2ccc(Cl)cc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.60
SMN1; SMN2 Q16637 6/20 0.60
NPC1 O15118 5/20 0.60
ALDH1A1 P00352 3/20 0.60
HTT P42858 2/20 0.60
POLB P06746 2/20 0.60
ALOX12 P18054 1/20 0.60
PPARG P37231 2/20 0.55
TP53 P04637 2/20 0.55
MAPT P10636 2/20 0.55
LMNA P02545 1/20 0.55
TSHR P16473 1/20 0.54
KDM4E B2RXH2 1/20 0.54
GAA P10253 1/20 0.54
CTDSP1 Q9GZU7 1/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C19 P33261 2/20 0.53
CA1 P00915 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15676733 0.89 RAB9A (0.63) RAB9ASMN1; SMN2NPC1ALDH1A1HTT
SCHEMBL1696365 0.89 HDAC6 (0.66) RAB9ASMN1; SMN2NPC1ALDH1A1HTT
SCHEMBL1696480 0.88 NPC1 (0.58) RAB9ASMN1; SMN2NPC1ALDH1A1POLB
SCHEMBL5333738 0.85 TSHR (0.66) RAB9ASMN1; SMN2NPC1ALDH1A1HTT
SCHEMBL1690500 0.85 RAB9A (0.59) RAB9ASMN1; SMN2NPC1ALDH1A1HTT
SCHEMBL1696390 0.84 MMP13 (0.64) RAB9ASMN1; SMN2NPC1ALDH1A1HTT
SCHEMBL18719480 0.83 SMN1; SMN2 (0.59) RAB9ASMN1; SMN2NPC1ALDH1A1HTT
SCHEMBL14233914 0.82 KAT6A (0.58) RAB9ASMN1; SMN2NPC1ALDH1A1POLB
SCHEMBL18773661 0.82 CA1 (0.67) RAB9ASMN1; SMN2NPC1ALDH1A1HTT
SCHEMBL1696341 0.81 L3MBTL1 (0.66) RAB9ASMN1; SMN2NPC1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-12 US disclosed
US-7453002-B2 thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS F12, F11, F5 RAB9A 818/4885SMN1; SMN2 4322/4885NPC1 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.